Clinical trial NCT04971876: Evaluation of the Safety and Performance of an Injectable Hyaluronic Acid Filler
Official title: Prospective, Interventional, Non-Randomized, Open Label Study for the Evaluation of the Safety and Performance of an Injectable Hyaluronic Acid Filler
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lips Enhancement
Nasolabial Fold Correction
Midface Volume Deficit
Lead sponsor: Hallura Ltd.
Sponsor class: INDUSTRY
First posted: 2021-07-22
Enrollment: 132
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of the safety and performance of the investigational device in its three concentrations for cheek and lips augmentation and correction of the nasolabial folds, assuming that the performance of the product will be demonstrated based on the responder rates observed compared to baseline.


Eligibility criteria: Inclusion Criteria:

* Healthy Subject;
* Male or female, over the age of 21;
* Seeking an aesthetic procedure on the face and can be classified into one of the following groups:

  1. Group1: Lip volume deficit with ROSSI score between 1.5 and 3 on at least the upper lip, or on both the upper and the lower lips with up to 1 point difference in ROSSI score between upper and lower lips;
  2. Group 2: Moderate to severe nasolabial folds (NLFs) with WSRS scale score 3 or 4 for each side of the face;
  3. Group 3: Mild to significant volume deficit at the cheeks level with MFVDS score 2 to 4 at each side, with up to 1 point difference in MFVDS scale score between the two sides.

     Investigator Live-Evaluator (ILE) and Injector must independently agree that the criteria is met, however concordance of the scores is not required.
* Willing to abstain from any aesthetic treatment on the face other than the treatments planned in the protocol during the study period.

Exclusion Criteria:

* Anything on the treatment site which might interfere with the evaluation (tattoo, scar, moles, too many hairs).
* Subject with mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g., juvenile dermatomyositis), partial lipodystrophy (e.g., Barraquer-Simons syndrome), inherited disease, or HIV-related disease, and/or severe malocclusion or dentofacial or maxillofacial deformities.
* Known history of multiple allergies, allergic/anaphylactic reactions including allergy to lidocaine or anaesthetics of the amide type, to hyaluronic acid products, or to Grampositive bacterial proteins.
* Inflammatory and/or infectious cutaneous disorders in or near the treatment area (herpes, acne, mycosis, papilloma, rosacea, blotches or other pathology on the treatment area, at the investigator appreciation). Subject with recurrent herpes is not eligible even if asymptomatic at time of inclusion.
* History or current autoimmune disease and/or immune deficiency.
* History of streptococcal disease (such as acute rheumatic fever or recurrent sore throats), precancerous lesions/skin malignancies, hyper- or hypo-pigmentation in face.
* Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders.
* Received (or is planning to receive) anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs \[oral/injectable corticosteroids or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, e.g., aspirin, ibuprofen)\], or other substances known to increase coagulation time from 10 days pre- to 3 days post injection \[Study device injections may be delayed as necessary to accommodate this 10-day washout period.\]
* Have received at any time permanent facial implants (e.g. polyacrylamide, silicone) anywhere in the face or neck.
* Botulinum toxin injections, mesotherapy, or resurfacing (laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative procedures) within 6 months prior to entry in the study.
* Have received injection with a temporary bioresorbable facial dermal filler (e.g., hyaluronic acid, collagen, autologous fat, etc.) within the past 12 months prior to study start.
* Have undergone semi-permanent dermal filler treatment (e.g., calcium hydroxylapatite, poly-L-lactic acid, etc.) in the face within 24 months before enrolment.
* Have received at any time a treatment with tensor threads or gold strands on the face.
* Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study.

Primary outcomes:
measure: Responder Rate
timeFrame: Month 3 for Group 1, Month 6 for Groups 2 and 3
Secondary outcomes:
measure: Aesthetic Improvement Based on Global Aesthetic Improvement Scale (GAIS) Subject and Investigator
timeFrame: Month 12
measure: Subject's Satisfaction Based on FACE-Q
timeFrame: Month 12
measure: Performance Based on ILE Scores Compared to Baseline
timeFrame: Month 12
Other outcomes:
Locations:
city: Darmstadt
country: Germany
facility: Rosenpark Research GmbH
city: Düsseldorf
country: Germany
facility: Private Practice Dr.Hilton & Partner GbR
city: Warszawa
country: Poland
facility: Centrum Medyczne Evimed
Study officials:
References: